Tuesday, April 21, 2015

Cantor upgrades Rosetta Genomics to buy

Cantor upgrades Rosetta Genomics to buy

April 17, 2015 by · Leave a Comment 

Tweet Cantor Fitzgerald has upgraded Rosetta Genomics (NASDAQ:ROSG) to “buy” from “hold” and raised its price target to $5.50 from $4, following the company’s acquisition of PersonalizeDx (PDx) from Abbott. The stock closed at $3.78 on Thursday. PDx is a CLIA lab started by Abbott about five years ago to provide oncology testing services, largely […]

HCW starts InVivo Therapeutics at buy

HCW starts InVivo Therapeutics at buy

April 17, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of InVivo Therapeutics Holdings (NASDAQ:NVIV) with a “buy” rating and $25 price target, saying the company’s technology targeting spinal cord injuries holds underappreciated value. The stock closed at $16.85 on Thursday. Analyst Andrew Fein writes that the company’s key value-driver, the Neuro-Spinal Scaffold for acute spinal cord injury (SCI), is […]

Nuvo Research outlines strategic plans

Nuvo Research outlines strategic plans

April 16, 2015 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) has examined strategic alternatives with a view to increasing shareholder value by obtaining better recognition of its assets. After examining alternative structures and transactions internally, and with the assistance of outside consultants, the company has determined that it should work towards spinning out WF10-related assets into a separate R&D focused entity […]

Avivagen issues CEO update

Avivagen issues CEO update

April 16, 2015 by · Leave a Comment 

Tweet Avivagen (TSX-V:VIV) CEO, Cameron Groome, has released a letter to shareholders that outlines the company’s recent accomplishments and notes that Avivagen and potential clients are planning further OxC-beta trials. Mr. Cameron also discusses developments regarding the company’s companion animal (pet) products and non-surgical sterilization project. A copy of the letter can be accessed here.

CombiMatrix launches buccal swab DNA collection

CombiMatrix launches buccal swab DNA collection

April 16, 2015 by · Leave a Comment 

Tweet CombiMatrix (NASDAQ:CBMX) has announced the availability of its new Buccal Swab DNA Collection system for the CombiSNP Array for Pediatric Analysis microarray test, effective May 1. The collection system uses a cheek swab in lieu of a blood draw, which provides a more comfortable and convenient way to collect samples from neonates and pediatric […]

Relmada cleared to further develop d-Methadone

Relmada cleared to further develop d-Methadone

April 16, 2015 by · Leave a Comment 

Tweet Relmada Therapeutics (OTCQB:RLMD) has received clearance from Health Canada to continue dose escalation and explore higher doses of d-Methadone (REL-1017), its N-methyl-D-aspartate receptor antagonist being developed for the treatment of neuropathic pain. In the Phase 1 pharmacokinetic and pharmacodynamic study in healthy volunteers not previously exposed to opioid therapy, d-Methadone demonstrated a good safety […]

Leerink reinstates Inogen to outperform

Leerink reinstates Inogen to outperform

April 15, 2015 by · Leave a Comment 

Tweet Leerink Partners has reinstated its “outperform” rating to Inogen (NASDAQ:INGN) and raised its price target to $40 from $36, after gaining more clarity into the ongoing internal accounting investigation. The stock closed at $34.54 on Tuesday. Analyst Danielle Antalffy writes that the issue, which prompted the internal investigation, is tied to a small number […]

Janney starts Raptor Pharma at buy

Janney starts Raptor Pharma at buy

April 15, 2015 by · Leave a Comment 

Tweet Janney Capital Markets has launched coverage of Raptor Pharmaceuticals (NASDAQ:RPTP) with a “buy” rating and a fair value estimate of $16. The stock closed at $10.58 on Tuesday. Raptor is focused on developing and commercializing therapies for rare diseases. The company has PROCYSBI (RP103) currently approved in the U.S. and EU to treat a […]

Cain expands healthcare team with Rafe Hanahan hire

Cain expands healthcare team with Rafe Hanahan hire

April 15, 2015 by · Leave a Comment 

Tweet Rafe Hanahan is joining Cain Brothers as a managing director to lead a team covering the medical devices and technology industries. Mr. Hanahan will work with public and private companies engaged in orthopedics, cardiovascular, wound care, contract manufacturing, and other sub-sectors in the medical technology industry. He will also be involved in the firm’s […]

Roth starts uniQure at buy

Roth starts uniQure at buy

April 14, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $38 price, saying its AAV-based gene therapy could usher in a new era in the treatment of multiple chronic and fatal disorders. The stock closed at $29.03 on Monday. “The 3Q and 4Q15 reads from its Hemophilia B and […]

Next Page »

Email Newsletters with Constant Contact
Google+